UB Paderborn / Katalog / Suche / in CDI

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

The Lancet (British edition), 2009-10, Vol.374 (9699), p.1432-1440

2009

Link zum Volltext

Verfügbarkeit prüfen

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

HemaSphere, 2023-08, Vol.7 (S3), p.e216416f-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.63-69

2012

Link zum Volltext

Verfügbarkeit prüfen

Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups

HemaSphere, 2020-12, Vol.4 (6), p.e485-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

Annals of neurology, 2020-10, Vol.88 (4), p.712-722

2020

Link zum Volltext

Verfügbarkeit prüfen

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

The Lancet. Haematology, 2020-03, Vol.7 (3), p.e196-e208

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Blood, 2018-11, Vol.132 (Supplement 1), p.3029-3029

2018

Link zum Volltext

Verfügbarkeit prüfen

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Blood, 2021-01, Vol.137 (3), p.387-391

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Blood, 2022-11, Vol.140 (Supplement 1), p.9663-9664

2022

Link zum Volltext

Verfügbarkeit prüfen

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Blood, 2019-11, Vol.134 (Supplement_1), p.1685-1685

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer

Clinical cancer research, 2006-12, Vol.12 (23), p.7071-7078

2006

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Blood, 2020-11, Vol.136 (Supplement 1), p.33-33

2020

Link zum Volltext

Verfügbarkeit prüfen

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Annals of hematology, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

Breast cancer research and treatment, 2008-07, Vol.110 (2), p.309-315

2008

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

Cancer investigation, 2012-05, Vol.30 (4), p.309-316

2012

Link zum Volltext

Verfügbarkeit prüfen

Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo

Canadian journal of physiology and pharmacology, 1996-01, Vol.74 (1), p.9

1996

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

Breast cancer research and treatment, 2008-07, Vol.110 (1), p.309

2008

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

Breast cancer research and treatment, 2008, Vol.110 (2), p.309-315

2008

Link zum Volltext

Verfügbarkeit prüfen

Effects of angiotensin-II infusion at pressor and subpressor doses on endothelbv-1 plasma levels in healthy men

Life sciences (1973), 1997-04, Vol.60 (21), p.1859-1866

1997

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine in non-small cell lung cancer (NSCLC)

Investigational new drugs, 2000-02, Vol.18 (1), p.29-42

2000

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

Ropeginterferon Alfa‐2b: Efficacy and Safety in Different Age Groups

Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

Effects of angiotensin-II infusion at pressor and subpressor doses on endothelbv-1 plasma levels in healthy men

Gemcitabine in non-small cell lung cancer (NSCLC)

Aktive Filter

Suchergebnisse filtern